Sage Therapeutics Newsroom

Half Year 2024 Results

16 May 2024Download the full press release (PDF)Strong performance driven by innovationSteve Hare, Chief Executive Officer, commented:"Sage performed well in the first half of the year, delivering bro

SAGE Sage TherapeuticsMay 16 00:00 ET

Sage Therapeutics CE Says Co Open To Partnership On Huntington's Drug; Says There Is A 'Lot Of Inbound Interest'

Sage Therapeutics CE Says Co Open To Partnership On Huntington's Drug; Says There Is A 'Lot Of Inbound Interest'

BenzingaMay 14 13:31 ET

SAGE Cyber Emerges From Stealth Mode - Announces the Launch of the SAGE Platform to Help CISOs With Cyber Defense Planning and Optimization

NEW YORK, May 13, 2024 /PRNewswire/ -- SAGE Cyber, the world's leading innovator of cybersecurity defense planning and optimization technology, is proud to announce it has emerged from stealth, and w

PR NewswireMay 13 08:57 ET

Major Depressive Disorder Pipeline Insights Report, 2024 Featuring 75+ Companies and Pipeline Drugs, Including SAGE-217 (Sage Therapeutics) and REL-1017 (Relmada Therapeutics)

Yahoo FinanceMay 8 04:43 ET

Sage Therapeutics to Participate in Upcoming May Investor Conferences

Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in the following upcoming investor

BusinesswireMay 7 06:30 ET

Sage Therapeutics Is Maintained at Overweight by JP Morgan

Sage Therapeutics Is Maintained at Overweight by JP Morgan

Dow JonesMay 1 11:33 ET

JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $28

JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:SAGE) with a Overweight and lowers the price target from $29 to $28.

BenzingaMay 1 11:24 ET

Express News | Sage Therapeutics Inc : JP Morgan Cuts Target Price to $28 From $29

ReutersApr 30 23:44 ET

Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript

Yahoo FinanceApr 30 12:57 ET

Novel Postpartum Depression Treatment Offers Upside Potential for Sage Therapeutics (NASDAQ:SAGE)

TipRanksApr 30 07:52 ET

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)

TipRanksApr 30 03:00 ET

Earnings Update: Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Are Boosting Their Estimates

Yahoo FinanceApr 28 08:33 ET

Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho

Sage Therapeutics Price Target Cut to $18.00/Share From $20.00 by Mizuho

Dow JonesApr 26 09:24 ET

Sage Therapeutics Is Maintained at Neutral by Mizuho

Sage Therapeutics Is Maintained at Neutral by Mizuho

Dow JonesApr 26 09:24 ET

Express News | Canaccord Genuity Maintains Hold on Sage Therapeutics, Lowers Price Target to $17

BenzingaApr 26 08:56 ET

SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks

TipRanksApr 26 08:35 ET

Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment

TipRanksApr 26 08:08 ET

SAGE Therapeutics (SAGE) Receives a Hold From RBC Capital

TipRanksApr 26 06:37 ET

SAGE Therapeutics' Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Rating

TipRanksApr 26 02:21 ET

Express News | Sage Therapeutics Inc : Canaccord Genuity Cuts Target Price to $17 From $21

ReutersApr 26 01:47 ET